JMP Securities Lowers OptimizeRx (NASDAQ:OPRX) Price Target to $8.00

OptimizeRx (NASDAQ:OPRX) had its price target trimmed by JMP Securities from $16.00 to $8.00 in a report issued on Thursday,Benzinga reports. The firm currently has a market outperform rating on the stock.

OPRX has been the subject of a number of other research reports. Barclays decreased their price objective on shares of OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating for the company in a report on Monday, August 12th. B. Riley began coverage on OptimizeRx in a report on Thursday, July 25th. They set a “buy” rating and a $18.50 target price for the company. Finally, Royal Bank of Canada lowered their price target on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, OptimizeRx currently has a consensus rating of “Moderate Buy” and an average price target of $10.42.

OptimizeRx Trading Down 5.9 %

Shares of NASDAQ:OPRX traded down $0.24 during trading hours on Thursday, hitting $3.82. 534,590 shares of the company’s stock traded hands, compared to its average volume of 142,274. The business has a fifty day moving average price of $6.67 and a 200-day moving average price of $9.03. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $16.65. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.27.

Hedge Funds Weigh In On OptimizeRx

Hedge funds and other institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC raised its holdings in shares of OptimizeRx by 5.1% during the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after purchasing an additional 89,377 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of OptimizeRx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock valued at $12,482,000 after buying an additional 6,291 shares during the period. AWM Investment Company Inc. grew its holdings in OptimizeRx by 4.0% during the first quarter. AWM Investment Company Inc. now owns 853,042 shares of the company’s stock worth $10,364,000 after acquiring an additional 33,000 shares during the period. Blair William & Co. IL lifted its holdings in OptimizeRx by 5.6% in the first quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock valued at $9,508,000 after acquiring an additional 41,469 shares during the period. Finally, Rice Hall James & Associates LLC boosted its position in OptimizeRx by 24.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after purchasing an additional 119,306 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.